Physician profile
Mandy D Gordon
NPI 1497195598
$12,198.42
in general payments reported to CMS, 2019-2025
64 companies · $3,294 in 2025
The $3,294 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,258 · 2022: $1,735 · 2023: $2,975 · 2024: $2,937 · 2025: $3,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,285 · Consulting Fee: $500 · Education: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,285.47 |
| Consulting Fee | $500.00 |
| Education | $420.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,733.04 | 2021-2025 | Datroway, Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $1,084.93 | 2021-2025 | Enhertu, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $1,059.42 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $791.26 | 2022-2025 | |
| Incyte Corporation | $580.83 | 2022-2025 | Monjuvi, Monjuvi, Jakafi |
| Glaxosmithkline, LLC. | $490.28 | 2021-2025 | Jemperli, Ojjaara, Zejula |
| Abbvie INC. | $482.67 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $440.76 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $436.35 | 2021-2023 | Blincyto, Lumakras, Kyprolis |
| Eisai INC. | $404.88 | 2021-2025 | |
| Pfizer INC. | $398.99 | 2022-2025 | |
| Genzyme Corporation | $246.17 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $221.54 | 2021-2025 | Fruzaqla, Ninlaro, Iclusig |
| Exelixis INC. | $219.12 | 2022-2025 | Cabometyx |
| Seagen INC. | $215.26 | 2021-2023 | Tukysa |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $193.83 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Puma Biotechnology, INC. | $176.24 | 2021-2025 | Nerlynx |
| E.R. Squibb & Sons, L.L.C. | $163.36 | 2022-2025 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $157.01 | 2021-2023 | Epkinly, Imbruvica |
| Regeneron Healthcare Solutions, INC. | $141.98 | 2022-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $136.18 | 2022-2025 | Fotivda |
| Genentech USA, INC. | $132.15 | 2021-2024 | Tecentriq, Phesgo, Perjeta |
| Emd Serono, INC. | $128.73 | 2023-2024 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $125.61 | 2021-2025 | Onivyde, Tazverik |
| Stemline Therapeutics INC. | $124.44 | 2024 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.86 | 2023-2025 | Gilotrif |
| Bayer Healthcare Pharmaceuticals INC. | $115.24 | 2021-2025 | |
| Sobi, INC | $106.00 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $104.75 | 2021-2025 | Qinlock, Romvimza |
| Celgene Corporation | $103.21 | 2022-2024 | Opdualag, Pomalyst |
| Astellas Pharma US INC | $101.25 | 2021-2025 | Xospata, Xtandi, Vyloy |
| Adc Therapeutics America, INC. | $91.19 | 2021-2023 | |
| Mirati Therapeutics, INC. | $86.13 | 2023 | Krazati |
| Beigene USA, INC. | $81.28 | 2021-2025 | Brukinsa |
| Tersera Therapeutics LLC | $73.04 | 2021-2025 | Xermelo, Zoladex |
| Beone Medicines USA, INC. | $71.87 | 2025 | Brukinsa, Tevimbra |
| Dova Pharmaceuticals | $67.83 | 2021 | |
| Pharmacosmos Therapeutics INC. | $65.98 | 2021-2024 | Monoferric |
| Pharmaessentia USA Corporation | $52.58 | 2022-2023 | Besremi |
| Iovance Biotherapeutics, INC. | $49.68 | 2024-2025 | Amtagvi |
| Array Biopharma INC | $47.49 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Janssen Scientific Affairs, LLC | $46.53 | 2023 | Tecvayli, Darzalex |
| Apellis Pharmaceuticals, INC. | $45.66 | 2023 | Empaveli |
| G1 Therapeutics, INC. | $44.31 | 2022-2023 | Cosela |
| Kyowa Kirin, INC. | $38.02 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $36.14 | 2022-2025 | Givlaari |
| Myovant Sciences INC. | $36.11 | 2021 | |
| Rigel Pharmaceuticals, INC. | $35.05 | 2022-2024 | Tavalisse, Rezlidhia |
| Janssen Pharmaceuticals, INC | $34.13 | 2021 | |
| Caris Mpi, INC. | $33.76 | 2025 | Mi Cancer Seek |
| Dendreon Pharmaceuticals LLC | $29.96 | 2022 | |
| Acceleron Pharma, INC. | $23.26 | 2021 | |
| Tempus Ai, INC | $20.12 | 2024 | |
| Ucb, INC. | $18.07 | 2023 | |
| Kite Pharma, INC. | $16.02 | 2023 | |
| Karyopharm Therapeutics INC. | $14.99 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.68 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.36 | 2021 | |
| Syndax Pharmaceuticals, INC. | $13.65 | 2025 | |
| Global Blood Therapeutics, INC. | $13.17 | 2022 | |
| Sumitomo Pharma America, INC. | $12.76 | 2023 | Orgovyx |
| Boston Scientific Corporation | $12.63 | 2022 | |
| Cti Biopharma Corp. | $12.58 | 2022 | |
| Taiho Oncology, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.